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Background: Non-medical, non-pharmacological and pharmacological treatments are recommended for the
prevention of migraine. The purpose of this randomized double-blind placebo controlled, multicenter trial was
to evaluate the efficacy of a proprietary nutritional supplement containing a fixed combination of magnesium,
riboflavin and Q10 as prophylactic treatment for migraine.
Methods: 130 adult migraineurs (age 18 – 65 years) with ≥ three migraine attacks per month were randomized
into two treatment groups: dietary supplementation or placebo in a double-blind fashion. The treatment period
was 3 months following a 4 week baseline period without prophylactic treatment. Patients were assessed before
randomization and at the end of the 3-month-treatment-phase for days with migraine, migraine pain, burden of
disease (HIT-6) and subjective evaluation of efficacy.
Results: Migraine days per month declined from 6.2 days during the baseline period to 4.4 days at the end of the
treatment with the supplement and from 6.2.days to 5.2 days in the placebo group (p = 0.23 compared to placebo).
The intensity of migraine pain was significantly reduced in the supplement group compared to placebo (p = 0.03).
The sum score of the HIT-6 questionnaire was reduced by 4.8 points from 61.9 to 57.1 compared to 2 points in
the placebo-group (p = 0.01). The evaluation of efficacy by the patient was better in the supplementation group
compared to placebo (p = 0.01).
Conclusions: Treatment with a proprietary supplement containing magnesium, riboflavin and Q10 (Migravent®
in Germany, Dolovent® in USA) had an impact on migraine frequency which showed a trend towards statistical
significance. Migraine symptoms and burden of disease, however, were statistically significantly reduced compared
to placebo in patients with migraine attacks.
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Migraine is a functional disorder of the brain. The patho-
physiology of migraine involves many different mechanisms
including modulation of central and peripheral pain struc-
tures and release of vasoactive peptides. Patients typically
experience episodes of headaches, mostly throbbing, unilat-
eral and severe which vary within and among patients.* Correspondence: c.gaul@migraene-klinik.de
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in any medium, provided the original work is pHeadaches are frequently accompanied by other symptoms
like nausea, phonophobia and/or photophobia [1].
Acute attacks are treated with different analgesics or
triptans. Only a minority of migraineurs take preventive
medication to decrease the frequency, duration and se-
verity of migraine attacks. Prophylactic drug treatment
of migraine should be considered when the quality of life
is severely impaired, when two or more attacks occur
per month, when migraine attacks do not respond to
acute drug treatment or in case of intolerance to or side
effects of acute treatment [2].Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Society and the American Academy of Neurology recom-
mend primarily beta-blockers, antiepileptics (topiramate or
valproic acid), and antidepressants (e.g. amitriptyline) for
migraine prevention [3,4]. Vitamin B2 (riboflavin), magne-
sium and coenzyme Q10 are alternatives to drugs and ap-
peal to patients with a desire for more natural treatment. In
addition, micronutrients are seen by the patients as a "mild"
form of treatment with no or minor side effects [5,6].
Studies revealed decreased levels of the micronutrients
riboflavin, magnesium and coenzyme in plasma and in the
brain of migraine patients [7-9]. A deficit of these nutrients
could play a role in the pathophysiology of migraine. Mito-
chondrial dysfunction is associated with migraine [10,11].
Riboflavin, magnesium and coenzyme Q10 play an import-
ant role in the production of energy in the mitochondria
[12]. Magnesium is needed in various physiological processes
which influence the pathophysiology of migraine (vasocon-
striction, platelet inhibition, secretion of serotonin). Magne-
sium is also needed as a co-factor for proper functioning of
the ATP-synthase which produces ATP. Furthermore, Mg is
the physiological antagonist at the NMDA-channel which is
involved in the regulation of neuronal excitability. Riboflavin
is a precursor for flavin-mononucleotide (FMN) and flavin-
adenine-dinucleotide (FAD). Both are essential components
of complex I and complex II responsible for electron-
transport in the mitochondrial membrane. Coenzyme Q10
is a vitamin-like compound which can be synthesized by
the body from phenylalanine and tyrosine. Coenzyme Q10
is needed for all cellular processes requiring energy. Coen-
zyme Q10 is an electron-carrier, transferring electrons from
complex I/complex II to cytochrome C. Based on these ob-
servations, it seems plausible that a substitution of these
micronutrients in migraine patients might be able to pre-
vent or reduce the intensity of migraine attacks. Migraine
treatment with a nutritional supplement might be of benefit
for patients with recurrent migraine who cannot tolerate
chemical drugs due to side effects or contra-indications due
to concomitant diseases.
The commercially available food supplement Migravent®
in Germany (Dolovent® in the USA) contains riboflavin,
magnesium and coenzyme in high doses along with low-
dose multi-vitamins for support of general health. This sup-
plement has already been tested in an open clinical study
with 31 migraine patients in Germany [13]. The present
trial was conducted to prove the efficacy of Migravent®/
Dolovent® compared to placebo in a larger number of pa-




Otherwise healthy adults aged 18 to 65 years of either sex
were recruited by neurologists practicing in Germany. Allparticipants had migraine with and without aura diag-
nosed according to the IHS-criteria ICHD-II 1.1 und 1.2
[14]. The age at onset of migraine was less than 50 years
of age and diagnosis of migraine was at least one year be-
fore study entry. The participants were required to have at
least 3 migraine attacks per month in the last 3 months
before recruitment and not more than 10 headache days.
Patients were excluded if they used migraine prevention
(drugs, nutritional supplements or psychotherapy) as well
as antipsychotic or antidepressant medication during the
last 3 months prior to study entry and throughout the
study. Patients with medication overuse were excluded.
Patients who had failed to respond to more than 2 differ-
ent prophylactic agents in the past and patients resistant
to all acute migraine drugs were not included.
The study was approved by the Institutional Review
Board for each center. All participants gave written in-
formed consent. The study was conducted according to
the ethics principles of the Declaration of Helsinki. The
trial was registered in the German Clinical Trial Register
DRKS00004565.
Interventions
The investigational nutritional product (INP) is a dietary
food for special medical purposes (according to EU regula-
tions) containing 400 mg riboflavin (vitamin B2), 600 mg
magnesium, 150 mg coenzyme Q10 along with a multivita-
min/trace elements combination per 4 capsules (Migravent®,
Dolovent®). The amount of additional multivitamin/trace ele-
ments per 4 capsules is as follows: 750 μg vitamin A, 200 mg
vitamin C, 134 mg vitamin E, 5 mg thiamin, 20 mg niacin,
5 mg vitamin B6, 6 μg vitamin B12, 400 μg folic acid, 5 μg
vitamin D, 10 mg pantothenic acid, 165 μg biotin, 0.8 mg
iron, 5 mg zinc, 2 mg manganese, 0.5 mg copper, 30 μg
chromium, 60 μg molybdenum, 50 μg selenium, 5 mg biofla-
vonoides. Placebo capsules indistinguishable from verum
were used as control. Patients were instructed to take two
capsules orally in the morning and two capsules in the even-
ing for 3 months. Treatments for other conditions which
may have an effect on migraine prevention were not allowed.
These were mainly beta-blockers (e.g. propranolol, biso-
prolol, metoprolol), calcium-antagonists (e.g. flunarizine),
antiepileptics (e.g. topiramate, valproate), antidepressants
(e.g. amitryptiline), supplements containing petasites (butter-
bur) or tanacetum (feverfew), magnesium, riboflavin or coen-
zyme Q10 in doses above 50 mg. Non-medical/non-nutritional
treatment for migraine prevention like acupuncture or
psychotherapy were also not permitted. However, partici-
pants were allowed to treat migraine attacks with their
usual rescue pain medication and anti-emetics.
Study design
The study was conducted as a randomized, placebo-
controlled, parallel-arm, double-blind, prospective multi-
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month baseline period without treatment to verify that
they had more than 3 migraine attacks but not more than
10 days with migraine or non-migraine headaches. The
baseline phase also served as a baseline for the evaluation
of efficacy parameters. Before entering the baseline phase
patients had to meet inclusion and exclusion criteria (see
Participants and recruitment). Demographic data, concomi-
tant medication, medical history, migraine diagnosis as well
as previous migraine preventive measures were docu-
mented by the investigator. Following the baseline phase
and provided no inclusion/exclusion criteria were violated,
eligible patients were randomized in double-blind fashion
to verum or to placebo (1:1). In this follow-up visit pa-
tients were also asked to fill in an HIT-6 questionnaire.
Randomization was done by computer and randomization
lists were prepared. Randomization was done by blocks of
four per center. The investigator sequentially allocated the
random numbers to patients, starting from the lowest
number. A blockwise randomization was used. The se-
quential order was verified by fax sent to a blinded person
at the sponsor and from entries in the screening logs. Both
investigator and patient were blinded to the treatments.
Treatment with either verum or placebo was for 3 months.
Migraine parameters and intake of the investigational
products were recorded daily by the patients throughout
the baseline and the treatment phase in an electronic diary
accessed online via the internet. Compliance (documenta-
tion, intake of investigational products) was monitored
regularly by the investigator and delegates of the sponsor.
Patients were immediately contacted by the investigator if
regular documentation was missing for more than a week.
At the follow-up visit at the end of the treatment the pa-
tients again had to fill in an HIT-6 questionnaire and they
were asked to evaluate the tolerability and efficacy of the
treatment from their view. Concomitant medication and
occurrence of adverse events were checked at each follow-
up visit. Compliance was assessed by a pill count of the
returned investigational product.
Efficacy parameters
The primary efficacy endpoint was defined as days with
migraine as recorded in the online diary by the patient.
Secondary endpoints were maximal pain of migraine
headaches as recorded in the online diary, migraine bur-
den as assessed through the HIT-6 questionnaire [15] and
subjective patient evaluation of efficacy.
Days with migraine and migraine pain intensity were
compared between the one-month baseline period and the
last month of the 3-month treatment. A migraine day was
defined as a day with at least 4 hours of migraine pain or a
day with migraine pain and concomitant intake of pain
medication. For each migraine day, pain intensity was rated
as mild, moderate or severe by the patient. The HIT-6questionnaire (headache impact test), which measures the
impact of headache on a patient´s life, was filled out by the
patient at the start of the treatment (randomization) and at
the end of the 3-month treatment. This validated ques-
tionnaire consists of 6 questions, each question or item
has the following response options: never (6 points), rare
(8 points), sometimes (10 points), very often (11 points)
and always (13 points) [14]. Headache impact on this scale
ranges from 36 (no headache) to 78 (very severe head-
ache). All checked points are added for the analysis. Effi-
cacy of the treatment as a subjective evaluation by each
patient was recorded at the end of the study as very good,
good, moderate or poor.
Statistical methods
The sample size estimation was performed with the Test
of the Ratio of Two Poisson Means module of PASS 11
software (NCSS, LLC. Kaysville, Utah, USA). A reduc-
tion by at least 50% in the number of migraine days
should be achieved in the verum group because this was
considered a clinically relevant improvement and a 30% re-
duction in the placebo group was assumed as the worst
case scenario since placebo effects of around 30% have
been seen in trials. Based on these assumptions, the esti-
mated sample size without compensation for drop-out is
39.2 ≈ 40 patients per treatment group, i.e. 80 patients in
total. The sample size was increased to 104 patients in total
to compensate for overdispersion and a 15% drop-out rate.
The statistical analysis was based on the ICH Topic E9
Note for guidance on statistical principles for clinical
trials (CPMP/ICH/363/96). A detailed description of the
statistical evaluation was provided in a Statistical Ana-
lysis Plan (SAP).
The primary endpoint migraine days was compared
statistically in a confirmatory test approach on superior-
ity of Migravent® compared to placebo. The respective
statistical test was performed using the generalized lin-
ear model in the following form: it was assumed that the
number of migraine days during the last month of the 3-
month treatment period can be described by Poisson
distributions. The migraine day rate depends on treat-
ment and disease severity at baseline, which is defined as
the number of migraine days during the one-month base-
line period. This was modeled through a Poisson regres-
sion with covariate “number of migraine days during the
one-month baseline period” and with the factors “treat-
ment” and “center”. The null hypothesis to be tested was
whether the rate ratio for treatment (ρ = λPlacebo/λVerum) is
smaller or equal to 1 (i.e. log rate ratio is smaller or equal
to 0). The type-I error rate was set to α = 0.025 (one-
sided). Confounding factors were not controlled for.
The maximal intensity of migraine pain per migraine
day during the last month of the 3-month treatment was
compared between treatment groups by an ANCOVA
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baseline period as baseline covariate.
The burden of disease measured by HIT-6 sum scores
for the end of treatment was compared between treatment
groups by an ANCOVA with the burden of disease sum
scores for the start of treatment as baseline covariate.
Subjective evaluation of efficacy by the patient at the
end of therapy was displayed by default descriptive sta-
tistics for continuous data as well as for categorical data.




173 migraine patients fulfilled the inclusion- and exclu-
sion criteria and were enrolled in the baseline phase.
The enrollment took place in 12 neurological centers in
Germany from October 2012 to November 2013. The
baseline phase consisted of a 30-day period without
prophylactic migraine treatment. 34 patients could not
be randomized into the treatment groups because they
failed inclusion and fulfilled exclusion criteria after base-
line; of the 34 patients, 4 had no migraine attack at all,
21 had between 1 and 2 migraine attacks per month and
9 had more than 10 days with migraine. Nine patientsFigure 1 Consort diagram showing recruitment and flow of participawere lost during the baseline phase, mostly due to non-
compliance with the use of the online diary. The number
of patients with prior migraine prevention was slightly
higher in the placebo group (40 vs 36), however, 3 vs 1 pa-
tients in the verum group had used more than 3 migraine
preventions in the past. The same, to a slightly more ex-
tent, is observed regarding medical history and concomi-
tant medications. Of the 130 patients randomized, one
patient provided no efficacy data since he did not open
the diary during the treatment phase and did not show up
for the final visit. Due to major protocol violations, 9 pa-
tients in the active-group and 8 patients in the placebo-
group were excluded from efficacy analysis (Figure 1).
The baseline characteristics of all patients included in
the efficacy analysis are described in Table 1. There was
no significant difference in baseline parameters. 37 pa-
tients (64.9%) in the placebo group had migraines without
aura compared to 28 patients (50.9%) in the active group.
The number of patients without any prophylactic mi-
graine treatments in their medical history was similar in
both groups. However, the number of patients with up to
3 different prophylactic treatments in the past was higher
in the placebo group (35.0%) than in the active group
(21.8%). Number of concomitant diseases and medications
was higher in the placebo group.nts through trial.
Table 1 Baseline characteristics of evaluable participants
Characteristic Verum Placebo
N = 55 N = 57
Female n (%) 48 (87.3) 49 (86.0)
Age y (SD) 40.4 (13.39) 36.4 (11.14)
BMI (SD) 23.16 (3.57) 23.17 (3.55)
Migraine type
With aura n (%) 22 (40.0) 16 (28.1)
Without aura n (%) 28 (50.9) 37 (64.9)
Previous migraine prevention
Participants with no previous
preventions n (%)
40 (72.7) 36 (63.2)
Participants with 1-3 previous
preventions n (%)
12 (21.8) 20 (35.0)
Participants with more than 3
previous preventions n (%)
3 (5.4) 1 (1.8)
Medical history, diseases n (%) 43 (42.1) 59 (57.8)
Concomitant medication n (%) 24 (36.3) 42 (63.6)
n denotes numbers, events or medication, respectively.
Table 3 Reduction of maximal pain per migraine day
Intensity (SD) Verum Placebo P value
N = 55 N = 57
Baseline 2.71 (0.458) 2.70 (0.533) -
Treatment 1st month 2.55 (0.503) 2.63 (0.620) 0.17
Treatment 2nd month 2.44 (0.572) 2.53 (0.630) 0.53
Treatment 3rd month 2.47 (0.639) 2.64 (0.520) 0.03
Patients (%) Verum Placebo P value
N = 55 N = 57
Baseline -
- mild 0 (0) 2 (3.5)
- moderate 16 (29.1) 13 (22.8)
- severe 39 (70.9) 42 (73.7)
Treatment 3rd month 0.03
- mild 4 (7.3) 1 (1.8)
- moderate 20 (36.4) 18 (31.6)
- severe 29 (52.7) 37 (64.9)
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Active treatment was able to reduce the number of days
with migraine from 6.2 days in the baseline-phase to
4.4 days after 3 month of treatment by 1.8 days (Table 2).
However, this reduction of migraine days compared to
placebo was not statistically significant (p = 0.23).
Maximal pain intensity per migraine day
Verum reduced the mean maximal pain intensity of a
migraine day based on a 3-point-scale by 0.24 points at
the end of the 3-month treatment. This reduction was
statistically significant compared to placebo (0.06 points,
p = 0.03) (Table 3). The percentage of patients with se-
vere pain was lower and the percentage of patients with
mild pain at the end of the 3-month treatment phase was
higher in the active group compared to placebo.
HIT-6 Questionnaire (headache impact test)
Verum reduced the sum score of the HIT-6 question-
naire by 4.8 points (from 61.9 points at baseline to 57.1
points at the end of the 3-month treatment). This reduc-
tion was statistically significant compared to placeboTable 2 Reduction of migraine days
Days with migraine (SD) Verum Placebo P value
N = 55 N = 57
Baseline 6.2 (1.95) 6.5 (1.78) -
Treatment 1st month 5.0 (3.39) 5.7 (3.03) 0.37
Treatment 2nd month 4.8 (3.29) 5.5 (3.01) 0.39
Treatment 3rd month 4.4 (2.99) 5.2 (3.22) 0.23(p = 0.01). The reduction of HIT-6 sum scores in the pla-
cebo group was 2 points (from 61.9 points to 59.9).
Evaluation of efficacy by the patient
At the end of the 3-month treatment, the efficacy as eval-
uated by the patient was statistically significantly superior
compared to placebo (p = 0.01) (Table 4). No patient in
the placebo group rated the efficacy as very good, whereas
18% of the patients treated with verum rated the efficacy
as very good. Nearly half of the patients in the placebo
group rated the efficacy as poor (43.9%) compared to only
29.1% in the active treatment group.
Safety
Adverse events were classified by System Organ Class
(SOC) and Preferred Term (PT) of the MedDRA-coding
system. The safety population consisted of n = 63 patients
in the verum group as well as in the placebo group. No
serious adverse events (SAE) were observed in this trial.
The incidence of adverse events (AE) was higher under
active treatment (34 AE in 21 (33.3%) of 63 patients) com-
pared to placebo (9 AE in 7 (11.1%) of 63 patients). All
adverse events whose causal relationship to the studyTable 4 Evaluation of efficacy by patient
Verum Placebo P value
N = 55 N = 57
Mean (SD) 2.6 (1.09) 3,2 (0.81) 0.01
very good n (%) 10 (18.2) 0 (0)
good n (%) 16 (29.1) 14 (24.6)
moderate n (%) 13 (23.6) 18 (31.6)
poor n (%) 16 (29.1) 25 (43.9)
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sibly related were classified as adverse reactions (AR). The
incidence of adverse reactions was higher under active
treatment (24 AR in 15 (23.8%) of 63 patients) compared
to (3 AR in 3 (4.8%) of 63 patients). The two most fre-
quent adverse reactions were gastrointestinal disorders
(verum: 10 AR in 8 (12.7%) of 63 patients; placebo: 2 AR
in 2 (3.2%) of 63 patients) mainly diarrhea and chroma-
turia (verum: 8 AR in 8 (12.7%) of 63 patients; placebo: 0
AR in 0 (0%) patients).
The majority of adverse reactions observed under ac-
tive treatment were completely recovered before the end
of the study (21 (87.5%) of 24 AR). While most adverse
reactions (13 AR (54.2%)) did not lead to any action re-
garding the study treatment, 3 (12.5%) adverse reactions
led to dose change, 6 (25%) adverse reactions to perman-
ent discontinuation of the active treatment and 2 (8.3%)
adverse reactions to another treatment.
Discussion
Drugs like metoprolol, propranolol, flunarizine, valproic
acid or topiramate have been shown in clinical trials to
be effective in reducing migraine symptoms when ad-
ministered as prophylactic agents in episodic migraine
[16-22]. All of these drugs have potential side effects,
sometimes of severe nature. For this reason many pa-
tients look for a natural preventive treatment of mi-
graine. In fact, some clinical trials have been performed
with magnesium [23-29], riboflavin (vitamin B2) [30-35]
or ubiquinone (ubichinon, coenzyme Q10) [36-38] mostly
as single agents. One RCT used a combination of magne-
sium, riboflavin and the botanical feverfew [31] which re-
vealed no advantage over the control group (intake of
25 mg riboflavin), most likely due to the fact that 25% -
38% of the patients in the verum and control group took
concomitant migraine prophylaxis during the study. To
the best of our knowledge, there is no report of a random-
ized, double-blind and controlled trial with a triple com-
bination of magnesium, riboflavin and coenzyme Q10. It
is interesting to note, that a pharmacogenomic study dem-
onstrated the importance of the mitochondrial genetic
background on response to riboflavin [39]. This under-
lines the role of the mitochondrion in migraine and the
potential role of magnesium, coenzyme Q10 and ribofla-
vin in alleviating migraine symptoms. It can also explain
why certain patients are non-responders.
Baseline values were comparable between the treat-
ment groups. The number of patients who used migraine
prevention before study entry was slightly higher in the
placebo group. The numbers are too small to be signifi-
cant and to have had an impact on the primary endpoint.
The same, to a slightly more extent is observed regarding
medical history and concomitant medications. Since pa-
tients were allocated in a strict randomized fashion toboth treatment arms this observation might be pure
chance. It is not justified to suggest that patients in one
group who seem to be slightly more ill than patients in
the other group would show a difference in the prevention
of migraine.
In this clinical trial, a combination of three natural nu-
tritional substances, magnesium, riboflavin and Q10, was
tested against placebo in the treatment of migraine in
adult patients. Treatment for 3 months with this propri-
etary nutritional supplement was able to reduce the
number of days with migraine by almost 2 days (1.8),
which is considered to be a clinically relevant reduction.
The reduction by placebo was 1.3 days. However, the re-
duction in migraine days was not statistically significant.
A very similar reduction was achieved in a random-
ized, placebo-controlled study (MIGR-003) with topira-
mate [19]. Migraine days were reduced by 1.8 days by
topiramate 100 mg/day and by 1.1 days by placebo. This
result was statistically significant (p = 0.026). However,
the number of patients in the 100 mg topiramate arm
was 139 compared to 55 in the arm of this trial with the
nutritional supplement containing a fixed combination
of magnesium, riboflavin and Q10. This suggests that the
trial might have been underpowered with regard to the
primary endpoint migraine days. The fact that the 200 mg
topiramate arm in the MIGR-003 study did not reach stat-
istical significance even with 143 patients (probably due to
many early drop-outs) suggests that 55 patients are simply
not enough to show statistical significance of any treat-
ment in reducing migraine days.
Otherwise, the secondary endpoints that were analyzed
in addition to the reduction of migraine days in this trial
demonstrated a statistically significant benefit of the
triple combination compared to placebo. Patients treated
with verum had a statistically significantly greater reduc-
tion in the maximally experienced pain per migraine day
compared to placebo (p = 0.03). In the verum group, 70.9%
of the patients reported severe migraine pain prior to treat-
ment. At the end of the treatment, only 52.7% had severe
pain, 7.3% had mild pain. In the placebo group, 73.7%
patients had severe pain in the baseline period, 64.9%
patients had severe pain at the end of treatment and only
1.8% patients had mild pain.
The beneficial efficacy of verum was also shown by a
statistically significant reduction in the score of the head-
ache impact test questionnaire HIT-6 (p = 0.01). The sum
score of the questionnaire was reduced in the active group
after 3 months of treatment by a mean of 4.8 points. A
primary care population of migraine patients was analyzed
in the publication by Smelt. A within-person minimal
important change (MIC) was established between -2.5
and -5.5 points depending on the statistical approach [40].
The within-person MIC is defined as the smallest change
in the score which patients perceive as important. The
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relevant improvement which shows statistical significance
compared to placebo. The HIT-6 questionnaire is a scale
with 5 response options. The response options never
(6 points), rarely (8 points) and always (13 points) are not
represented in the study population because those patients
were excluded from participation based on the inclusion
and exclusion criteria. Therefore, sometimes (10 points)
and very often (11 points) are left as the only possible an-
swers for the study population, with only a 1-point difference
between them. This 1-point difference in the questionnaire
corresponds to a relevant difference in medical terms or
in terms of disease burden/headache impact. A 4.8 point
reduction translates into nearly 5 items (questions in the
questionnaire) being improved from very often to some-
times. Smelt also established a between-group minimally
important difference (MID) of -1.5 points [40]. Similar to
the within-person MIC, the between-group MID is the
smallest difference between scores of groups of patients that
is considered important. The difference between the placebo
group and the verum group was -2.8 points in this trial.
In agreement with the above result, the evaluation of
efficacy of the preventive treatment was better for verum
than for placebo. The difference was statistically signifi-
cant (p = 0.01). 18.2% of the patients in the active group
rated the efficacy as very good, none in the placebo
group. Nearly 50% (47.3%) of the patients rated the effi-
cacy “very good” or “good” which was twice as many as
in the placebo group. Also, the number of patients rating
efficacy as poor was higher in the placebo group.
These results indicate that the study preparation might
have had an impact on the frequency of migraine days
and improved clinically relevant prespecified secondary
endpoints such as pain intensity, headache impact on life
(HIT-6) and subjective evaluation of effectiveness.
The triple combination had a favorable adverse event
profile. Adverse events usually observed with drugs like
weight gain, depression, tiredness or dizziness were not
observed.
A shortcoming is the possibility of unblinding patients
in the verum group due to chromaturia. However, every
patient was told at the beginning of the trial that a dis-
coloration of the urin might appear in order to rule out
that chromaturia would be associated with verum only.
The only way to avoid this would have been to add ribo-
flavin to placebo.
The strength of this study is the prospective, double-
blind and placebo-controlled design. The study was pow-
ered to show a possible difference for the primary end-
point. The study used validated endpoints.
Conclusions
A fixed combination in a daily dose of 600 mg magne-
sium, 400 mg riboflavin and 150 mg Q10 in a proprietarynutritional supplement including also various low-dose
multivitamins did not show statistically significant efficacy
in the reduction of migraine days probably due to being
underpowered. It did, however, prove to be superior for
several secondary outcomes in the treatment of migraine.
After 3 months of treatment with the supplement, a re-
duction of migraine pain and burden of disease was seen.
Patients rated the efficacy of the treatment significantly
superior to placebo. Adverse events associated with the
supplement were mainly abdominal discomfort and diar-
rhea due to high amounts of magnesium. There were no
serious adverse events reported in this trial.Competing interests
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